Phathom Pharmaceuticals Inc (NASDAQ: PHAT) started the day on Wednesday, remained unchanged at $2.40, before settling in for the price of $2.40 at the close. Taking a more long-term approach, PHAT posted a 52-week range of $2.38-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 1600.29%. Meanwhile, its Annual Earning per share during the time was 12.50%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.05%. This publicly-traded company’s shares outstanding now amounts to $69.64 million, simultaneously with a float of $38.78 million. The organization now has a market capitalization sitting at $167.55 million. At the time of writing, stock’s 50-day Moving Average stood at $4.85, while the 200-day Moving Average is $10.02.
Phathom Pharmaceuticals Inc (PHAT) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Phathom Pharmaceuticals Inc’s current insider ownership accounts for 44.45%, in contrast to 59.86% institutional ownership. According to the most recent insider trade that took place on Apr 07 ’25, this organization’s CFO and CBO sold 3,678 shares at the rate of 4.55, making the entire transaction reach 16,740 in total value, affecting insider ownership by 89,868. Preceding that transaction, on Mar 13 ’25, Company’s Director bought 10,000 for 4.42, making the whole transaction’s value amount to 44,200. This particular insider is now the holder of 85,500 in total.
Phathom Pharmaceuticals Inc (PHAT) Earnings and Revenue Records
Phathom Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 40.05% and is forecasted to reach -0.47 in the upcoming year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Let’s observe the current performance indicators for Phathom Pharmaceuticals Inc (PHAT). It’s Quick Ratio in the last reported quarter now stands at 3.54. The Stock has managed to achieve an average true range (ATR) of 0.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.05.
In the same vein, PHAT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -5.24, a figure that is expected to reach -0.94 in the next quarter, and analysts are predicting that it will be -0.47 at the market close of one year from today.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
If we take a close look at the recent performances of Phathom Pharmaceuticals Inc (NASDAQ: PHAT), its last 5-days Average volume was 3.45 million that shows progress from its year to date volume of 1.28 million. During the previous 9 days, stock’s Stochastic %D was recorded 1.08% While, its Average True Range was 0.43.
Raw Stochastic average of Phathom Pharmaceuticals Inc (PHAT) in the period of the previous 100 days is set at 0.37%, which indicates a major fall in contrast to 1.20% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 126.46% that was higher than 107.92% volatility it exhibited in the past 100-days period.
